Literature DB >> 22676135

miR-297 modulates multidrug resistance in human colorectal carcinoma by down-regulating MRP-2.

Ke Xu1, Xin Liang, Ke Shen, Daling Cui, Yuanhong Zheng, Jianhua Xu, Zhongze Fan, Yanyan Qiu, Qi Li, Lei Ni, Jianwen Liu.   

Abstract

Colorectal carcinoma is a frequent cause of cancer-related death in men and women. miRNAs (microRNAs) are endogenous small non-coding RNAs that regulate gene expression negatively at the post-transcriptional level. In the present study we investigated the possible role of microRNAs in the development of MDR (multidrug resistance) in colorectal carcinoma cells. We analysed miRNA expression levels between MDR colorectal carcinoma cell line HCT116/L-OHP cells and their parent cell line HCT116 using a miRNA microarray. miR-297 showed lower expression in HCT116/L-OHP cells compared with its parental cells. MRP-2 (MDR-associated protein 2) is an important MDR protein in platinum-drug-resistance cells and is a predicted target of miR-297. Additionally miR-297 was down-regulated in a panel of human colorectal carcinoma tissues and negatively correlated with expression levels of MRP-2. Furthermore, we found that ectopic expression of miR-297 in MDR colorectal carcinoma cells reduced MRP-2 protein level and sensitized these cells to anti-cancer drugs in vitro and in vivo. Taken together, our findings suggest that miR-297 could play a role in the development of MDR in colorectal carcinoma cells, at least in part by modulation of MRP-2.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22676135     DOI: 10.1042/BJ20120386

Source DB:  PubMed          Journal:  Biochem J        ISSN: 0264-6021            Impact factor:   3.857


  29 in total

Review 1.  MicroRNA Pharmacoepigenetics: Posttranscriptional Regulation Mechanisms behind Variable Drug Disposition and Strategy to Develop More Effective Therapy.

Authors:  Ai-Ming Yu; Ye Tian; Mei-Juan Tu; Pui Yan Ho; Joseph L Jilek
Journal:  Drug Metab Dispos       Date:  2015-11-13       Impact factor: 3.922

2.  MicroRNAs associated with inflammation in shoulder tendinopathy and glenohumeral arthritis.

Authors:  Finosh G Thankam; Chandra S Boosani; Matthew F Dilisio; Devendra K Agrawal
Journal:  Mol Cell Biochem       Date:  2017-06-20       Impact factor: 3.396

Review 3.  MicroRNAs in colorectal cancer as markers and targets: Recent advances.

Authors:  Jing-Jia Ye; Jiang Cao
Journal:  World J Gastroenterol       Date:  2014-04-21       Impact factor: 5.742

Review 4.  Multidrug Resistance Proteins (MRPs) and Cancer Therapy.

Authors:  Yun-Kai Zhang; Yi-Jun Wang; Pranav Gupta; Zhe-Sheng Chen
Journal:  AAPS J       Date:  2015-04-04       Impact factor: 4.009

Review 5.  Molecular pathways involved in microRNA-mediated regulation of multidrug resistance.

Authors:  Rongrong Liao; Yuexia Lin; Lihui Zhu
Journal:  Mol Biol Rep       Date:  2018-09-07       Impact factor: 2.316

Review 6.  MicroRNAs and their relevance to ABC transporters.

Authors:  Sierk Haenisch; Anneke Nina Werk; Ingolf Cascorbi
Journal:  Br J Clin Pharmacol       Date:  2014-04       Impact factor: 4.335

Review 7.  MicroRNAs are important regulators of drug resistance in colorectal cancer.

Authors:  Yang Zhang; Jing Wang
Journal:  Biol Chem       Date:  2017-07-26       Impact factor: 3.915

Review 8.  An update on miRNAs as biological and clinical determinants in colorectal cancer: a bench-to-bedside approach.

Authors:  Wenhao Weng; Junlan Feng; Huanlong Qin; Yanlei Ma; Ajay Goel
Journal:  Future Oncol       Date:  2015       Impact factor: 3.404

9.  miR-297 acts as an oncogene by targeting GPC5 in lung adenocarcinoma.

Authors:  Yunchuan Sun; Jianyong Zhao; Xiaoming Yin; Xiangkun Yuan; Jianfei Guo; Jianqiang Bi
Journal:  Cell Prolif       Date:  2016-08-24       Impact factor: 6.831

10.  Long noncoding RNA SPRY4-IT1 is upregulated in esophageal squamous cell carcinoma and associated with poor prognosis.

Authors:  Hai-Wei Xie; Qing-Quan Wu; Bin Zhu; Fang-Jun Chen; Lv Ji; Su-Qing Li; Chun-Mei Wang; Yu-Suo Tong; Lei Tuo; Ming Wu; Zhi-Hua Liu; Jin Lv; Wei-Hong Shi; Xiu-Feng Cao
Journal:  Tumour Biol       Date:  2014-05-09
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.